Выбор темы
Выбор стиля шрифта
Gilead Sciences новости
15/03
GILD - Сделка Инсайдера: продажа 11 марта 2022
16/02
💡
МНЕНИЕ: Квартальный отчет Gilead Sciences: слабый квартал и прогноз на 2022 г. - SUVE
12/02
GILD - Сделка Инсайдера: продажа 09 февраля 2022
03/02
GILD - Сделка Инсайдера: продажа 01 февраля 2022
02/02
🔗
Benzinga: GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead
02/02
🔗
Zacks Investment Research: Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges
02/02
🔗
Benzinga: Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
02/02
🔗
Seeking Alpha: Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q4 2021 Results - Earnings Call Transcript
02/02
🔗
Zacks Investment Research: Gilead Sciences (GILD) Q4 Earnings Miss Estimates
02/02
🔗
Reuters: GSK announces $1.25 billion settlement between ViiV Healthcare, Gilead
02/02
🔗
Market Watch: Gilead earnings slammed by legal settlement, stock falls
02/02
🔗
Reuters: Gilead earnings dip due to legal settlement, other charges
01/02
🔗
Zacks Investment Research: Big Data for Q4, Econ to Start a New Month
01/02
🔗
Zacks Investment Research: Should Value Investors Pick Gilead Sciences (GILD) Stock?
31/01
🔗
The Motley Fool: Is Gilead Sciences Stock a Buy Now?
28/01
🔗
Zacks Investment Research: Should You Buy Gilead Sciences (GILD) Ahead of Earnings?
28/01
🔗
Zacks Investment Research: Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
27/01
🔗
Zacks Investment Research: Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
25/01
🔗
Zacks Investment Research: Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
25/01
🔗
Zacks Investment Research: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
24/01
🔗
Zacks Investment Research: Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients
19/01
🔗
Benzinga: Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs
19/01
🔗
GuruFocus: Pharma Giants Go After $10 Billion Market With RSV Drugs
19/01
🔗
Business Wire: Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
18/01
🔗
Benzinga: Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US
16/01
🔗
The Motley Fool: 3 Pharma Stocks With Especially Juicy Dividends
10/01
🔗
Seeking Alpha: Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on JPMorgan 40th Annual Healthcare Conference (Transcript)
10/01
🔗
CNBC Television: Gilead CEO: Oral version of Covid drug Remdesivir in early testing
07/01
🔗
Seeking Alpha: Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
07/01
🔗
Seeking Alpha: Gilead: Veklury Revenues Set To Impress
06/01
🔗
Seeking Alpha: Gilead Sciences: A Good Pick For Value And Dividend Investors
05/01
🔗
Zacks Investment Research: Why Gilead (GILD) is Poised to Beat Earnings Estimates Again
05/01
🔗
The Motley Fool: 2 Top Dividend Stocks That Are Yielding More Than 3%
30/12
🔗
Seeking Alpha: My Top 10 Stocks For 2022
29/12
🔗
Zacks Investment Research: Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
29/12
🔗
Zacks Investment Research: GILD or VIR: Which Is the Better Value Stock Right Now?
29/12
🔗
Zacks Investment Research: Gilead (GILD) Hits Fresh High: Is There Still Room to Run?
29/12
🔗
Seeking Alpha: 10 Dividend Growth Stocks For December 2021
29/12
🔗
Zacks Investment Research: Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
23/12
🔗
Benzinga: Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
23/12
🔗
Seeking Alpha: Omicron: Good News, If It Can Be Slowed Down
22/12
🔗
Benzinga: FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir In HIV Trials
22/12
🔗
Business Wire: Gilead Sciences to Present at Upcoming Investor Conference
21/12
🔗
Benzinga: European Commission Expands Use Of Remdesivir In COVID-19 Patients Not On Supplemental Oxygen
17/12
🔗
GuruFocus: Analysts Project Sales of Gilead Drug Could Reach $1.5 billion
17/12
🔗
Zacks Investment Research: Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
14/12
🔗
Benzinga: Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
13/12
🔗
Benzinga: Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
11/12
🔗
Business Wire: Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
07/12
🔗
The Motley Fool: Is Gilead Sciences Stock a Buy Now?
06/12
🔗
Benzinga: Gilead Recalls Two Lots Of Remdesivir Due To Presence Of Glass Particulates
03/12
🔗
Seeking Alpha: Gilead Sciences: Opportunity Versus Irrelevant Value Trap
03/12
🔗
Seeking Alpha: Gilead Sciences, Inc. (GILD) Management Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)
26/11
🔗
Zacks Investment Research: Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
02/11
МНЕНИЕ: Выручка и прибыль Gilead Sciences выросли благодаря продажам Veklury - SUVE
09/08
МНЕНИЕ: Gilead Sciences отчиталась лучше ожиданий - SUVE
Загрузить еще